Licensor of Elast-Eon polymers to medical device industry

RUA Biomaterials is the depository of the Intellectual Property and licensing rights to a range of biostable, implantable polymers, including Elast-Eon and ECSilthe world’s leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA.

With well over seven million long term implants and fourteen years of successful clinical use, these polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae and stent devices. Devices manufactured from RUA Biomaterials polymers have numerous US FDA PMA approvals, 510k’s, CE Marks, Australian TGA and Japanese Ministry of Health approvals as well as FDA material master files.

World Leading Biomedical Polymer Technology

RUA Biomaterials technologies have been designed to improve the performance and reliability of existing medical devices and provide medical device designers with advantages and design options that were not available prior to the commercialization of our high performance polymer technologies.

Our business model is based on licensing our polymer technology to medical device companies. We then work as a partner with the device company to assist with their development programs resulting in a cost effective and rapid move to device registration and revenues.

As part of this model, RUA Biomaterials has sub-contracted manufacturing to Biomerics who supplies polymers and can also manufacture components for the partner.

Our sister company RUA Medical is becoming an Elast-Eon Academy and can assist in developing manufacturing techniques and can also manufacture devices and components.

With well over seven million implants and 14 years of successful clinical use, RUA Biomaterials polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and implantable sensor technology. Devices manufactured from RUAs polymers have numerous US FDA PMA approvals, 510k’s, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon and ECSil’s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

Leading Biomedical Research

The RUA team has worked with some of the worlds leading biomedical academics and medical professionals to understand the fundamental nature of its biomedical polymers.

This deeper level of understanding has allowed RUA Biomaterials to invent and launch superior biologically stable polymers and processes which we believe will facilitate the creation of next generation devices.

RUA Life Sciences Plc Videos

RUA Life Sciences - investor webinar July 2021 (FY results presentation) - Video

RUA LIfe Sciences` Chairman Trading Update Interview - Video

RUA Life Sciences Management Presentation June 2020 - Video

RUA Life Sciences - Investor Presentation discussing 510k submission and EACTS conference - Video

RUA Life Sciences AGM interview with CEO and Chairman - Video